BACKGROUND/OBJECTIVES: Prospectively collected data on postoperative delirium (POD) after transcatheter aortic valve implantation (TAVI) are scarce. The aim of this study was to report the incidence and risk factors of delirium after TAVI under general anesthesia and to assess the association of POD with clinical outcome and short-and long-term survival. DESIGN: Prospective cohort study. SETTING: Academic medical center. PARTICIPANTS: A total of 703 subsequent patients undergoing TAVI under general anesthesia between 2008 and 2017. MEASUREMENTS: Delirium was assessed according to the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV), criteria. Outcomes were postprocedural clinical outcome and short-and long-term survival (30 days and 5 years, respectively). RESULTS: POD was observed in 16.5% (116/703), was the strongest independent predictor of long-term mortality (hazard ratio = 1.91; 95% confidence interval [CI] = 1.36-2.70), and was associated with impaired 30-day and 5-year survival (92.2% vs 96.8% [P = .025] and 40.0% vs 50.0% [P = .007], respectively). Stroke and new onset of atrial fibrillation were more often observed in delirious patients (6.9% vs 1.9% and 12.1% vs 5.1%, respectively). Strongest independent predictors of POD were prior delirium (odds ratio [OR] = 2.56; 95% CI = 1.52-4.31) and aortic valve area less than 0.75 cm 2 (OR = 2.39; 95% CI = 1.53-3.74). CONCLUSION: One in six patients experienced POD after TAVI under general anesthesia. POD was the strongest predictor of long-term mortality and was associated with impaired short-and long-term survival. Prior delirium and a more calcified aortic valve were the strongest independent predictors of POD.
P ostoperative delirium (POD), primarily an alteration in attention, represents a decompensation of cerebral function in response to one or more pathophysiological stressors, such as major surgery. It occurs frequently after cardiac surgery (incidence = 11%-46%), 1 and has been associated with long-lasting functional and cognitive impairment, 2 increased social and economic burden, and increased risk of mortality. 3 Transcatheter aortic valve implantation or replacement (TAVI or TAVR, respectively) has emerged as the preferred management strategy for patients with severe, symptomatic aortic valve stenosis. [4] [5] [6] Annually, approximately 180 000 European and North American patients are considered potential TAVI candidates. 7 Given their advanced age and multiple comorbidities, these patients are at risk for developing POD.
Retrospective POD studies, based on a maximum of 300 patients, described in-hospital POD incidences of 12% to 53% after TAVI and focused on differences between treatment strategies (eg, surgical vs TAVR or different access routes for TAVI). 3, [8] [9] [10] [11] [12] The reported use of general anesthesia varied in these studies between 19% and 100% of patients. Larger patient data, based on clinical modification codes, have been analyzed but question the true incidence of POD since they report much lower rates of POD. 13, 14 Prospective data on the incidence and long-term consequences of delirium in large TAVI populations are not available.
The aim of the current study is to assess the incidence of POD after TAVI under general anesthesia, to assess the association of POD with short-and long-term survival, and to identify risk factors associated with the occurrence of POD.
METHODS
In this single-center study, we analyzed all consecutive patients treated with TAVI at the Radboud University Medical Center (Nijmegen, The Netherlands) between December 2008 and December 2017. Treatment allocation was performed by a dedicated heart team, according to the current guidelines. 15 General anesthesia was used in all patients, according to the local protocol. At the beginning of our TAVI program in 2008, the left axillary artery was selected as the primary access site in most patients. Over the years, this strategy changed toward a "femoral first" strategy. As for valve types implanted, Medtronic Cor-eValve and EvolutR were predominantly used. Additional procedural details and complications have been described previously. 16, 17 
Study outcomes
The primary end point of the study was the occurrence of delirium during hospitalization after TAVI under general anesthesia. The definition of POD was based on the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV), 18 and was defined as an acute and fluctuating disturbance of consciousness with reduced ability to focus, maintain, or shift attention, accompanied by change in cognition and perceptual disturbances secondary to a general medical condition. The occurrence of delirium was assessed by a trained nurse, physician, or member of the geriatric in-hospital CareWell program by means of the Confusion Assessment Method, 19 which was performed three times a day. A delirium observational score (DOS) was used in case delirium was suspected or diagnosed. This way, further evolution (signs) of delirium could be monitored. 20 In case of DOS of 3 or greater, a geriatrician was consulted to either confirm or exclude the diagnosis of delirium. 18 State-of-the-art prevention and management of POD was guided by a geriatric team and consisted of both pharmacological and nonpharmacological treatments, such as improvement of orientation, early mobilization, promotion of sleep, and the provision of vision and hearing adaptations. 19 Clinical outcome, including device success, was registered according to the updated Valve Academic Research Consortium-2 criteria. 21 Mortality tracking on all patients was performed on November 23, 2018, by consulting the Central Bureau for Statistics (The Hague, The Netherlands). Median follow-up at that time was 1290 (interquartile range [IQR] = 744-2039) days. All data were collected in an electronic data capturing system. Missing data or extreme values were excluded from analysis. Overall, the percentage of missing values (including mortality) did not exceed 1%. Given the observational design of the study, obtaining written informed consent was deemed unnecessary. Current analysis was approved by the institution's ethics committee and complies with the Declaration of Helsinki.
Statistical Analysis
Normality was tested using the Kolmogorov-Smirnov test. Categorical variables are expressed as frequencies and percentages and were compared using the χ 2 or Fisher's exact test. Continuous variables are expressed as mean and SD if normally distributed or as median and IQR if skewed and compared using the Student t or Mann-Whitney U test, respectively.
The effect of POD on 30-day and 5-year survival was visualized using Kaplan-Meier survival estimates, and difference in cumulative survival was tested using the log-rank test. Precipitating factors for POD were analyzed using univariate and multivariable binary logistic regression analyses. Univariate associated factors from Table 1 were offered for backward stepwise multivariable analysis with entry and exclusion limits at 0.05 and 0.10, respectively. Risk factors of 3-year mortality (selected based on the median follow-up duration of >3 years) were analyzed using Cox regression analysis based on variables from baseline and postoperative complications, including POD. Again, backward stepwise analysis with entry and exclusion limits of 0.05 and 0.10, respectively, were used. Independent risk factors for POD and 3-year mortality were reported as odds ratio (OR) and hazard ratio (HR) with 95% confidence intervals (CIs), respectively. Collinearity diagnostics were evaluated for all variables considered for multivariable analysis. In case of multicollinearity, the variable with the higher OR or HR was incorporated into the model. All tests were two tailed, and P < .05 was considered statistically significant. Analyses were performed using IBM SPSS Statistics software, version 25.0.0.1 (IBM Corp) and illustrated with GraphPad Prism, version 5.03 (GraphPad Software Inc).
RESULTS
In total, 703 consecutive TAVI patients were analyzed in the current study. Baseline characteristics are summarized in Table 1 and presented according to the occurrence of POD. POD was observed in 116 patients (16.5%). On average, POD occurred a median of 1 (IQR = 1-2) days after TAVI, and lasted for a median of 3 (IQR = 2-6) days ( Supplementary  Table S1 ).
POD and Clinical Outcome
Thirty-day survival after successful TAVI was significantly lower in patients with POD (92.2% vs 96.8%; P = .034). Consistently, long-term follow-up showed impaired 1-year (75.0% vs 86.5%; P = .002), 3-year (57.3% vs 69.4%; P = .001), and 5-year (40.0% vs 50.0%; P < .001) survival in patients with POD ( Figure 1 ). In multivariable Cox regression analysis with correction for several baseline characteristics (including age, sex, body mass index (BMI), creatinine, chronic obstructive pulmonary disease (COPD), permanent atrial fibrillation, and peripheral artery disease), POD was the strongest independent predictor of 3-year mortality (HR = 1.91; 95% CI = 1.36-2.70; P < .001) (Figure 2 , Supplementary Table S2 ).
Complications that were more frequently observed in patients with POD were stroke (6.9% vs 1.9%; P = .007), infection (20.7% vs 10.6%; P = .002), and new onset of atrial Supplementary Table S3 ). (Figure 3 , Supplementary Table S4 ): prior delirium (OR = 2.56; 95% CI = 1.52-4.31; P < .001), AVA less than 0.75 cm 2 (OR = 2.39; 95% CI = 1.53-3.74; P < .001), age (OR = 1.08; 95% CI = 1.04-1.12; P < .001), and BMI (OR = 0.94; 95% CI = 0.90-0.99; P = .018).
Baseline Characteristics Related to POD

Procedural Characteristics and POD
Device success was achieved in 93.6% of all patients and did not differ between patients with or without POD (92.2% vs 93.9%; P = .513). Axillary access was used in most patients (75.1%), and its use did not differ between patients with or without POD (80.2% vs 74.1%; P = .167). No significant differences in POD rates were observed between axillary access vs nonaxillary access (17.9% vs 12.6%; P = .096). No difference in procedural duration was observed between patients with or without POD (51 [42-70] vs 52 [41-65] minutes; P = .555). Conversion to surgical aortic valve replacement was required in six patients due to migration (n = 2), ectopic deployment (n = 2), or tamponade (n = 2). POD was observed in all these six patients ( Supplementary Table S5 ).
DISCUSSION
After TAVI under general anesthesia, POD is observed in 16.5% of patients. Independent risk factors for POD are older age, lower BMI, smaller AVA, and prior delirium. POD resulted in significant prolongation of hospital stay and decreased shortand long-term survival. In multivariable analysis, POD was identified as the strongest predictor of 3-year mortality. A recent meta-analysis illustrated the scarcity of data regarding POD after TAVI, with the largest included study describing retrospectively collected data of 294 patients. 3, 22 They described an overall pooled incidence of POD of 23%. Small retrospective studies concerning POD after transarterial TAVI reported incidences varying between 8% and 18%, 3, [8] [9] [10] [11] [12] and the higher incidences are mainly based on transapical TAVI procedures (incidence = 33%-60%). Larger studies, based on registered clinical modification codes, reported much lower incidences of 5% to 7%, which potentially led to underestimation of the true incidence of POD. 13, 14 Our prospectively collected data in the largest reported cohort so far show that POD after TAVI under general anesthesia occurs in one of six patients.
Baseline characteristics of the present study represent a patient population that is comparable to other studies. 8, 10, 11 Older age, lower BMI, and a history of delirium were identified as precipitating factors for POD. 1 Lower BMI is a known frailty indicator that can be a result of malnutrition, chronic disease, or stressors of acute-on-chronic disease (eg, exacerbations of COPD or congestive heart failure). Potential inherent sarcopenia and hypoalbuminemia are known risk factors for delirium. 23 Smaller AVA (<0.75 cm 2 ), which is considered an expression of overall calcium/atherosclerotic burden and possibly lower cerebral perfusion, 24 was also found to be associated with POD. However, procedural time and contrast use did not significantly differ between both groups. Theoretically, a higher grade of calcification could result in more complex procedures with respect to accessibility, necessity of predilatation and/or postdilatation, and repositioning. As a result, embolization of atherosclerotic debris could cause (subclinical) cerebral microinfarctions that are known to be associated with neurological and cognitive impairment. 25 Carotid artery disease, defined as prior or present carotid occlusion or stenosis of more than 50%, was not identified as a precipitating factor of POD in our population, which is in contrast to one of the main findings of the recent meta-analysis of Tilley et al. 22 Based on two different retrospective studies, 9, 11 they described a four times higher risk of POD for patients with carotid artery disease. However, ORs were based on a mix of univariate and multivariate OR data and included transapical procedures, which had the highest OR in that same meta-analysis.
Preoperative use of psychoactive medication could not be identified as a precipitating factor of POD in our population. Conflicting evidence exists on the effect of psychoactive medication use prior to surgery on the incidence of POD. Whenever an association was found, preoperative use of psychoactive medication (not corrected for comorbidity) could lead to a twofold to seven-fold higher risk of POD. 26 However, as in our study, psychoactive medication often included a range of medications, such as benzodiazepines, antidepressants, and antipsychotic medication; and indications for use were heterogeneous.
General anesthesia was used in all patients in the current study. Globally, a trend toward less invasive and more minimalistic approaches is being observed in which more and more general anesthesia is replaced by either conscious sedation or local anesthesia. Retrospective and matched studies suggest a less complicated postprocedural course with lower incidences of delirium in patients treated with local anesthesia or conscious sedation. 27 Moreover, it is conceivable that factors, such as infection due to intubation, narcotics, admission on different departments, and prolonged hospital stay, could provoke the development of POD in patients treated under general anesthesia. 27 Still, prospective randomized data are lacking, and true data on the incidence of POD in both treatment regimens remain unknown. New prospective data objectifying the incidence of POD with comparison between these anesthetic regimens are currently awaited (clinicaltrials.gov; NCT02786264).
Axillary access was predominantly used in our TAVI population (75.1%) and could not be related to POD. This is in contrast to previous studies that did identify nonfemoral access as an independent risk factor for POD. [8] [9] [10] [11] 28 However, the term "nonfemoral access" in these studies was mainly based on either transapical or direct aortic results and biased by patient selection. Transaxillary TAVI was used in less than 1% of all patients in these studies 3, [8] [9] [10] [11] [12] [13] [14] and, therefore, no conclusion regarding this access and POD has been drawn so far. In our center, the axillary access has been used as default access for many years and in this setting did not lead to an increased risk for POD.
In-hospital stroke was observed in 2.7% of all patients and was, like new onset of atrial fibrillation, more frequently present in patients with POD. Prior or new cerebral lesions, caused by either previously unknown or newly diagnosed atrial fibrillation, combined with embolization during TAVI may have caused cerebral frailty, eventually leading to the observed cognitive alteration. 29 Cerebral embolic protection devices, which capture embolic debris and reduce the occurrence of new brain lesions, were recently introduced but are still under debate. 30, 31 Stroke reduction is hard to investigate given its overall low incidence. Therefore, supported by cerebral imaging, POD might be useful as a surrogate outcome for stroke or as a primary outcome in future cerebral protection trials.
Short-and long-term survival were severely impaired in patients who had experienced POD, and POD remained an independent predictor of 3-year mortality when corrected for several baseline characteristics (Figures 1 and 2 and Supplementary Table S2 ). POD might be an expression of extreme vulnerability with diminished reserve capacity, but since delirium may be preventable in 30% to 40% of cases, 1, 32 future research should focus on adequate identification and prevention of POD to circumvent the associated burden of downstream complications and costs. Improvement of patient-tailored treatment, implementation of more minimalistic approaches, and recognition of risk factors will hopefully lead to a decrease in incidence of POD after TAVI.
Limitations
Results are based on a single-center experience with predominantly axillary access. However, potentially contributory, frailty assessment was not included in the current analysis. Axillary access was not associated with POD when compared to femoral access. Also, we cannot provide data on POD after TAVI using local anesthesia or conscious sedation and, hence, cannot draw any conclusion on the risk of general anesthesia for the risk of POD. We are aware of the fact that routine assessment of POD is currently not part of standard clinical practice. However, we hope that this study will raise awareness of delirium so that it will become part of perioperative care.
CONCLUSION
In the current study, we show that POD occurs in one of six patients after TAVI under general anesthesia and is independently associated with decreased short-and long-term survival.
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